Vivian Choi
Vice President, Liver Programs and Nonclinical Development, Prime Medicine, Inc.
Vivian Choi is listed as Vice President, Liver Programs and Nonclinical Development, Prime Medicine, Inc.. Vivian is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Vivian. Is this you? Claim this profile.
About
Vivian Choi is the Vice President of Liver Programs and Nonclinical Development at Prime Medicine and she previously led the Liver, Lung, Metabolic, Eye and Ear group at Prime, overseeing multiple portfolio programs and functions. Before joining the biotech industry, she built and led gene therapy research organizations at Novartis, Shire and Takeda with increasing responsibilities and providing scientific and strategic leadership to advance programs from discovery through clinical translation. Her experience spans viral and non-viral delivery, gene transfer, gene regulation, and genome editing across ophthalmic, neuromuscular, lysosomal storage, and rare liver diseases. Her academic training focused on AAV biology and delivery, in vivo gene therapy, and DNA recombination and repair. She earned a B.S. in Biochemistry from the University of Wisconsin-Madison, a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill and completed postdoctoral training at Harvard Medic
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel discussion Speaker · 19 January 2027
- Session 4: Genome and epigenome editing: troubleshooting the pathway to clinic and the marketplace beyond Speaker · 19 January 2027
- Session 4: How and where to harness NAMs in support of in vivo preclinical models in practice? Learning lessons from recent regulatory responses to IND applications Speaker · 20 January 2027
- Spotlight: Leveraging Prior Knowledge to Accelerate the Development of Multiple Liver-Directed Prime Editors Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Vivian at events on B2DB.
- Gregory Whitehead Executive Vice President & Chief Technical & Quality Officer · Editas Medicine 2 shared sessions
- Kate Excoffon American Society for Gene and Cell Therapy · American Society of Gene & Cell Therapy 1 shared session